Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With ...

Zura Bio launches TibuSURE, a Phase 2 study evaluating tibulizumab for systemic sclerosis, targeting anti-BAFF and IL-17 pathways.